Operations Specialist, Procurement & Administration - Part-time Temporary at Abata Therapeutics

Seattle, Washington, United States

Apply Now

Not SpecifiedCompensation

Entry Level & New Grad, Junior (1 to 2 years)Experience Level

Part TimeJob Type

UnknownVisa

BiotechnologyIndustries

Requirements

3-5+ years of procurement and general administrative experience within a life sciences/lab environment
BA, BS or equivalent combination of education and experience
Experience with procurement systems such as Quartzy/Netsuite or similar system
Detail oriented, reliable, and able to interact with employees and vendors in a professional manner
Thrive in a fast-paced and collaborative environment
Proficiency in Google Suite or equivalent (docs, sheets, slides, gmail) as well as MS Office Suite (Word, Excel)
Comfortable and have experience working in a scientific lab environment

Responsibilities

Tackle administrative tasks that keep office and lab operations systems efficiently on track (i.e. file management, tracking systems, guest & employee experience operations, inventories, receiving, etc.)
Initiate purchase orders for a biotech lab and office via Purchase Order or credit card
Monitor orders and ensure on-time delivery of all material
Negotiate prices and terms with suppliers, recommend suppliers with respect to cost, quality, and availability/schedule
Track, restock & reorder inventory for common-use stockroom supplies
Assist with tasks related to Cajal’s June 2026 facility relocation, such as vendor & other administrative updates
Partner with Finance/Accounts Payable to facilitate returns and other vendor follow-ups, as needed
Take on other tasks and projects as part of our lean and flexible operations team

Skills

Procurement

Purchase Orders

Inventory Management

Vendor Negotiation

Supplier Management

Administrative Tasks

File Management

Order Tracking

Accounts Payable

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free